Women with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have previously received an aromatase inhibitor have slower disease progression when everolimus is added to tamoxifen compared to women who receive tamoxifen alone, according to the results of a phase 2 trial released at the 33rd Annual San Antonio Bre...
More...